Entrada Therapeutics (TRDA) Retained Earnings (2020 - 2026)

Entrada Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$312.8 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 113.23% year-over-year to -$312.8 million; the TTM figure through Mar 2026 stood at -$312.8 million (down 113.23% YoY), while the FY2025 annual figure was $652000.0, up 100.5% from the prior year.
• Retained Earnings for Q1 2026 stood at -$312.8 million, down from $652000.0 in the prior quarter.
• The five-year high for Retained Earnings was $441.1 million in Q1 2024, with the low at -$312.8 million in Q1 2026.
• The 5-year median for Retained Earnings is $621000.0 (2025), against an average of $111.8 million.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 27800.98% in 2023, then plunged 66430.26% in 2024.
• Entrada Therapeutics' Retained Earnings stood at $402.9 million in 2022, then slumped by 99.95% to $195000.0 in 2023, then slumped by 66430.26% to -$129.3 million in 2024, then soared by 100.5% to $652000.0 in 2025, then slumped by 48077.15% to -$312.8 million in 2026.
• Business Quant data shows TRDA's Retained Earnings at -$312.8 million in Q1 2026, $652000.0 in Q4 2025, and $621000.0 in Q3 2025.